Narrow search
Showing 1 - 10 of 1,437
Cover Image
Erratum
Adis International Limited - In: PharmacoEconomics 30 (2012) 1, pp. 81-81
Persistent link: https://www.econbiz.de/10009421259
Cover Image
Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders
Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619
Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be … national health economic guidelines about the inclusion or exclusion of these costs. For those studies that did include …
Persistent link: https://www.econbiz.de/10011005068
Cover Image
Is There a Role for Pharmacoeconomics in Developing Countries?
Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436
Persistent link: https://www.econbiz.de/10011005069
Cover Image
Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34
cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic … the bibliographic databases PubMed, EMBASE and Health Economic Evaluations (HEED) [via the Cochrane Library] for …
Persistent link: https://www.econbiz.de/10011005070
Cover Image
Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777
Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...
Persistent link: https://www.econbiz.de/10011005071
Cover Image
Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
Augestad, Liv Ariane; Rand-Hendriksen, Kim; … - In: PharmacoEconomics 30 (2012) 12, pp. 1203-1214
Background:Background: National EQ-5D value sets are developed because preferences for health may vary in different … populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were … national value sets. Participants in the UK and US studies assessed the same subset of 42 EQ-5D health states using the time …
Persistent link: https://www.econbiz.de/10011005072
Cover Image
Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis
Byford, Sarah; Barrett, Barbara; Despiégel, Nicolas … - In: PharmacoEconomics 29 (2011) 2, pp. 157-170
Background: Research has consistently demonstrated a relationship between depression and increased levels of health … economic impact of non-remission on health service use and costs over 12 months from the index episode in patients with … health service use and cost over the 12-month study period, by remission status, where remission is defined as patients not …
Persistent link: https://www.econbiz.de/10011005073
Cover Image
Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
Hiligsmann, Mickal; Reginster, Jean-Yves - In: PharmacoEconomics 29 (2011) 10, pp. 895-911
Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...
Persistent link: https://www.econbiz.de/10011005074
Cover Image
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ghatnekar, Ola; Hjortsberg, Catharina; Gisslén, Magnus … - In: PharmacoEconomics 28 (2010) S1, pp. 49-57
Introduction: Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the...
Persistent link: https://www.econbiz.de/10011005075
Cover Image
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
Soares, Marta O.; Canto e Castro, Lusa - In: PharmacoEconomics 30 (2012) 12, pp. 1101-1117
The design of decision-analytic models for cost-effectiveness analysis has been the subject of discussion. The current work addresses this issue by noting that, when time is to be explicitly modelled, we need to represent phenomena occurring in continuous time. Models evaluated in continuous...
Persistent link: https://www.econbiz.de/10011005076